Kaletra: Therapy With Double Protease Inhibitors - Full Text View

Purpose

Therapy with lopinavir/ritonavir (Kaletra) and one other protease inhibitor in Human Immunodeficiency Virus participants

Condition
Human Immunodeficiency Virus

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	PMOS: Kaletra Double Protease Inhibitors

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Lopinavir

U.S. FDA Resources

Further study details as provided by AbbVie:

Primary Outcome Measures:

Percentage of Participants With Human Immunodeficiency Virus -1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ] [ Designated as safety issue: No ]
Viral load (number of HIV-1 RNA copies in the blood) was measured at baseline and scheduled study visits. A decrease in viral load is a measure used to assess the effectiveness of antiviral treatments. The percentage of participants with HIV RNA less than 50 copies/mL at each time point is presented.

Secondary Outcome Measures:

Change From Baseline in Absolute CD4 Cell Count [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ] [ Designated as safety issue: No ]
Increases in CD4 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD4+ cells at scheduled study visits.
Change From Baseline in Relative CD4 Cell Count [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ] [ Designated as safety issue: No ]
Increases in relative CD4 count (the percentage of total lymphocytes that are CD4 cells) are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD4-positive (CD4+) T-lymphocyte counts were assessed by measuring the change from Baseline in the percentage of CD4+ cells at scheduled study visits.
Change From Baseline in Absolute CD8 Cell Count [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ] [ Designated as safety issue: No ]
Decreases in CD8 count are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD8-positive (CD8+) T-lymphocyte counts were assessed by measuring the change from Baseline in the number of CD8+ cells at scheduled study visits.
Change From Baseline in Relative CD8 Cell Count [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ] [ Designated as safety issue: No ]
Decreases in relative CD8 count (the percentage of total lymphocytes that are CD8 cells) are a biomarker for antiretroviral treatment effectiveness in restoring immunologic function. Changes in participants' CD8-positive (CD8+) T-lymphocyte counts were assessed by measuring the change from Baseline in the percentage of CD8+ cells at scheduled study visits.
Change From Baseline in CD4/CD8 T-cell Ratio [ Time Frame: Baseline (Week 0), Weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 ] [ Designated as safety issue: No ]
The CD4/CD8 T-cell ratio, also known as the T-lymphocyte helper/suppressor profile, presents the number of lymphocytes in the blood positive for CD4 cells compared with the number positive for CD8 cells. Changes in participants' CD4/CD8 T-lymphocyte ratio were assessed by measuring the change from Baseline in the ratio at scheduled study visits.

Enrollment:	65
Study Start Date:	January 2004
Study Completion Date:	September 2011
Primary Completion Date:	September 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
HIV-infected participants HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor. Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily).

Detailed Description:

This study is intended to observe and collect data on the usage, dosing, tolerability, and effectiveness of lopinavir/ritonavir (Kaletra) when used as part of a Nucleoside Reverse Transcriptase Inhibitors-free double protease regimen. Enrollment in the study was independent of the decision to prescribe Kaletra.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Community sample; Human Immunodeficiency Virus-infected participants

Criteria

Inclusion Criteria:

Participants with Human Immunodeficiency Virus infection
Participants on lopinavir/ritonavir (Kaletra) and one other protease inhibitor

Exclusion Criteria:

Hypersensitivity against lopinavir, ritonavir or other ingredients
Severe liver insufficiency
No concomitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01075191

Locations

Germany
Site Reference ID/Investigator# 28109
Berlin, Germany, D-10243
Site Reference ID/Investigator# 48283
Berlin, Germany, 10439
Site Reference ID/Investigator# 28131
Berlin, Germany, 10551
Site Reference ID/Investigator# 66422
Berlin, Germany, 10961
Site Reference ID/Investigator# 28123
Berlin, Germany, 13347
Site Reference ID/Investigator# 28115
Dortmund, Germany, 44137
Site Reference ID/Investigator# 28127
Frankfurt, Germany, 60329
Site Reference ID/Investigator# 28124
Frankfurt, Germany, 60311
Site Reference ID/Investigator# 28119
Frankfurt, Germany, 60596
Site Reference ID/Investigator# 5318
Krefeld, Germany, 47800
Site Reference ID/Investigator# 28112
Ludwigshafen, Germany, 67063
Site Reference ID/Investigator# 28129
Muenster, Germany, 48149
Site Reference ID/Investigator# 28111
Muenster, Germany, 48143
Site Reference ID/Investigator# 28113
Munich, Germany, 80801
Site Reference ID/Investigator# 28118
Munich, Germany, 80337
Site Reference ID/Investigator# 28133
Stuttgart, Germany, 70197
Site Reference ID/Investigator# 28126
Wuppertal, Germany, 42277

Sponsors and Collaborators

AbbVie (prior sponsor, Abbott)

Investigators

Study Director:

Stefan Simianer, MD

AbbVie Deutschland GmbH & Co. KG, Medical Department

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:	NCT01075191 History of Changes
Other Study ID Numbers:	P05-103
Study First Received:	February 23, 2010
Results First Received:	September 28, 2012
Last Updated:	January 14, 2013
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AbbVie:

Viral load
Resistance
Double protease inhibitors
Mutations

Immune system
Infection
Nucleoside Reverse Transcriptase Inhibitors-free
Human Immunodeficiency Virus

Additional relevant MeSH terms:

Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

Protease Inhibitors
Reverse Transcriptase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Nucleic Acid Synthesis Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 18, 2013